- Home
- BFST vs SVRA Comparison
BFST vs SVRA Comparison
Compare BFST & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BFST | SVRA |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2014 | 2009 |
Fundamental Metrics
Financial Performance| Metric | BFST | SVRA |
|---|---|---|
| Price | $32.36 | $4.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $37.05 | $11.06 |
| AVG Volume (30 Days) | 160.1K | ★ 2.4M |
| Earning Date | 10-26-2026 | 11-20-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | ★ 23.45 | N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $10,704,000.00 | N/A |
| Revenue This Year | $14.30 | N/A |
| Revenue Next Year | $6.61 | $4,336.88 |
| P/E Ratio | $15.86 | ★ N/A |
| Revenue Growth | ★ 1.20 | N/A |
| 52 Week Low | $24.19 | $3.95 |
| 52 Week High | $33.60 | $7.01 |
Technical Indicators
Market Signals| Indicator | BFST | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 58.38 | 51.01 |
| Support Level | $30.86 | $4.73 |
| Resistance Level | N/A | $5.47 |
| Average True Range (ATR) | 0.86 | 0.32 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 57.69 | 70.15 |
Price Performance
Historical ComparisonAbout BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).